分化型甲状腺癌患者接受放射性碘治疗后的原发性乳腺癌风险:系统评价与荟萃分析
该研究通过PRISMA系统检索PubMed、Scopus和Web of Science数据库,纳入14项研究共200,247例分化型甲状腺癌患者(98,368例接受放射性碘治疗,101,879例未接受)。荟萃分析显示,接受放射性碘治疗的患者原发性乳腺癌的合并相对风险为0.83(95%CI 0.70-0.99),异质性为71.5%,作者认为放射性碘治疗不增加乳腺癌风险。
要点
- 分化型甲状腺癌患者接受放射性碘治疗与未接受者相比,原发性乳腺癌合并相对风险为0.83(95%CI 0.70-0.99)。
- 研究间异质性为71.5%,各研究相对风险范围为0.45至2.55。
- 作者结论认为放射性碘治疗不增加原发性乳腺癌风险。
核心结论
- 该荟萃分析表明,接受放射性碘治疗的分化型甲状腺癌患者与未接受者相比,原发性乳腺癌风险未升高,作者认为放射性碘治疗不增加乳腺癌风险。
研究设计与样本
- 按照PRISMA声明对PubMed、Scopus和Web of Science数据库进行系统文献检索。
- 最终分析纳入14项研究,共200,247例分化型甲状腺癌患者,其中98,368例接受放射性碘治疗,101,879例未接受放射性碘治疗。
- 计算接受与未接受放射性碘治疗患者原发性乳腺癌的相对风险,并合并效应量、评估异质性。
主要发现
- 各研究中接受放射性碘治疗者与未接受者相比的原发性乳腺癌相对风险范围为0.45至2.55。
- 合并相对风险为0.83(95%CI 0.70-0.99)。
- 异质性为71.5%。
关键数值与推荐
- 接受放射性碘治疗的分化型甲状腺癌患者原发性乳腺癌合并相对风险为0.83(95%CI 0.70-0.99)。
- 各研究间相对风险范围为0.45至2.55,异质性为71.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 异质性为71.5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although it has been proven that radioactive iodine (RAI) treatment is an effective and well-tolerated procedure in patients with differentiated thyroid cancer (DTC), there is still some concern regarding the risk of developing a second primary malignancy after RAI administration. We performed a systematic review and meta-analysis to investigate the risk of primary breast cancer in patients with DTC undergoing RAI therapy. METHODS: A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement. RESULTS: The final analysis included 14 studies accounting for a total of 200,247 patients with DTC (98,368 treated with RAI and 101,879 not treated with RAI). The relative risk of primary breast cancer in patients with DTC treated with RAI to those not treated with RAI among studies ranged from 0.45 to 2.55, the pooled relative risk was 0.83 (95% confidence interval, 0.70-0.99), and the heterogeneity was 71.5%. CONCLUSION: The present meta-analysis indicates that patients with DTC treated with RAI do not have a higher risk of primary breast cancer compared to those not treated with RAI. These findings suggest that RAI therapy does not increase the risk of breast cancer.
引用
- Nappi C, Klain M, Cantoni V, et al. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021. PMID: 34820683. doi:10.1007/s00259-021-05625-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。